Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 123M | 24.6% |
| Gross Profit | 67M | 124.1% |
| Cost of Revenue | 56M | 18.4% |
| Operating expense | 44M | 25.7% |
| Net Income | 41M | 75.3% |
| EBITDA | 64M | 74.4% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 706M | 9.2% |
| Total Liabilities | 98M | 14.6% |
| Total Equity | 609M | 8.4% |
| Shares Outstanding | 119M | 0.4% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 64M | 100.9% |
| Cash from investing | -10,000 | 95% |
| Cash from financing | 1.2M | 99.2% |
EPS
Financial Highlights for Catalyst Pharmaceuticals in Q2 '24
Catalyst Pharmaceuticals reported a revenue of 123M, which is a 24.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 67M, marking a 124.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 56M, a -18.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 44M, showing a -25.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 41M, showing a 75.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 64M, showing a 74.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Catalyst Pharmaceuticals with growth in revenue, gross profit, and net income.
